Holen Sie sich die Stockscreener-App
1.2693
10.00%
-0.1307
Schlusskurs vom Vortag:
$1.40
Offen:
$1.39
24-Stunden-Volumen:
693.78K
Relative Volume:
0.17
Marktkapitalisierung:
$5.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.083
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
-42.20%
1M Leistung:
-30.00%
6M Leistung:
-50.49%
1J Leistung:
-83.24%
1-Tages-Spanne:
$1.25
$1.39
1-Wochen-Bereich:
$1.25
$2.22
52-Wochen-Spanne:
$0.3975
$10.35
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
1.265 | 5.82M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.49 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.01 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.79 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.35 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.35 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
MGO Global, Moleculin Biotech, and Sacks Parente Golf Lead Penny Stock Surge - PUNE.NEWS
Moleculin Announces FDA Guidance for MIRACLE Trial Acceleration in Relapsed or Refractory AML - DocWire News
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech (NASDAQ:MBRX) Enters Into Warrant Exercise Inducement Agreement - Defense World
Moleculin Biotech Receives FDA Guidance for Phase 3 Trial on Annamycin-Cytarabine Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants -February 13, 2025 at 01:33 pm EST - Marketscreener.com
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Benzinga
Moleculin Biotech secures $5.8 million from warrant exercise - Investing.com
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Stock market news: Tantech Holdings declined by 97.05% while Moleculin Biotech surged by 590.48% during midday trading - Business Upturn
Moleculin Secures Critical $5.8M Funding: Strategic Warrant Deal Doubles Future Potential - StockTitan
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine - MSN
Moleculin (MBRX) Stock Rallies On Positive Regulatory Developments - Stocks Telegraph
Moleculin's Phase 3 AML trial gets FDA nod for size reduction - Investing.com
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
Stock market today: Tantech Holdings declined by 97.39% while Moleculin Biotech surged by 354.76% in early trading - Business Upturn
Moleculin Biotech Gets FDA Nod for Phase 3 Trial - TipRanks
Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks
Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia - Marketscreener.com
FDA Accelerates Game-Changing Leukemia Treatment Trial: Moleculin's Non-Cardiotoxic Solution Shows Promise - StockTitan
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy? - AOL
Moleculin Biotech (NASDAQ:MBRX) Receives First Country Regulatory Approval in Europe for Phase 3 Clinical Trial Protocol for Annamycin Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com India
Moleculin Announces First European Approval for Phase 3 AML Trial By Investing.com - Investing.com Nigeria
Moleculin Biotech Enters into Waiver and Consent Agreement with Investor - Defense World
The Significance of Moving Averages in Moleculin Biotech Inc Inc. (MBRX) Price Performance - The InvestChronicle
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
MBRX’s price-to-free cash flow ratio: What it means for investors - US Post News
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - The Malaysian Reserve
Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial - Marketscreener.com
Moleculin Biotech Gains European Approval for Phase 3 Trial - TipRanks
Moleculin Biotech receives first approval in Europe for AML trial recruiting - TipRanks
Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial - Marketscreener.com
Moleculin Biotech (MBRX) First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - StreetInsider.com
Major Milestone: Moleculin (MBRX) Secures Critical European Green Light for Groundbreaking AML Treatment Trial - StockTitan
Moleculin Biotech reaches agreement to amend investor warrants By Investing.com - Investing.com Australia
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
Moleculin Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Closing Bell Recap: Moleculin Biotech Inc (MBRX) Ends at 0.84, Reflecting a -15.27 Downturn - The Dwinnex
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Pediatric Brain Tumors Pipeline 2024: Latest FDA Approvals, - openPR
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor Segment: 8-K Filing Reveals - Defense World
Moleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor “What this Means” segment – 8-K Filing News - Defense World
Comparing Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Shares Updates on MIRACLE Trial - TipRanks
Amendment: Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Launches MIRACLE Study for AML - TipRanks
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):